Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial Fibrillation
NCT07877519
Summary
This prospective, multicenter, randomized, controlled, noninferiority trial will compare local anesthesia with conscious sedation and general anesthesia in patients undergoing pulsed field ablation for paroxysmal atrial fibrillation. A total of 390 participants aged 18 to 80 years will be randomly assigned in a 1:1 ratio to undergo pulsed field ablation under either local anesthesia with conscious sedation or general anesthesia. Both groups will receive pulmonary vein isolation using the same pulsed field ablation strategy. The primary outcome is recurrence of an electrocardiographically documented atrial tachyarrhythmia after an 8-week post-ablation blanking period. Recurrence is defined as atrial fibrillation, atrial flutter, or atrial tachycardia lasting at least 30 seconds through 12 months after ablation. The study will also compare the ability of each anesthesia strategy to support successful completion of the ablation procedure, anesthesia-related and ablation-related complications, procedural efficiency, patient-reported pain and anxiety, overall procedural experience, and direct medical costs.
Eligibility
Inclusion Criteria: 1. Diagnosis of paroxysmal atrial fibrillation. 2. Age 18 to 80 years. 3. Scheduled and willing to undergo pulsed field ablation. 4. American Society of Anesthesiologists physical status class I to III. 5. Able to understand the study procedures and provide written informed consent. Exclusion Criteria: 1. Contraindication to catheter ablation, including intracardiac or atrial thrombus. 2. Previous catheter ablation for atrial fibrillation or left atrial premature contractions. 3. Known allergy to iodinated contrast media. 4. Concurrent participation in another clinical trial involving a drug or medical device. 5. Pregnancy, breastfeeding, or planned pregnancy in the near future. 6. Active infection. 7. Unwilling to participate or unable to comply with the study procedures and scheduled follow-up.
Conditions2
Interventions9
Related trials
- A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma — Novartis Pharmaceuticals
- Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels — Maria Joyera Rodríguez
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients — Hangzhou Sumgen Biotech Co., Ltd.
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) — Merck Sharp & Dohme LLC
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma — University of Birmingham
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) — Nanjing IASO Biotechnology Co., Ltd.
- A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma — Qilu Pharmaceutical Co., Ltd.
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma — Hoffmann-La Roche
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07877519